(Q38481437)

3 September 2017

title

Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretations and positive attitudes (English)

1 reference

3 September 2017

1 reference

I Pellegrini

1

1 reference

3 September 2017

M Rapti

2

1 reference

3 September 2017

J-M Extra

3

1 reference

3 September 2017

A Petri-Cal

4

1 reference

3 September 2017

T Apostolidis

5

1 reference

3 September 2017

J-M Ferrero

6

1 reference

3 September 2017

T Bachelot

7

1 reference

3 September 2017

P Viens

8

1 reference

3 September 2017

C Julian-Reynier

9

1 reference

3 September 2017

F Bertucci

10

1 reference

3 September 2017

language of work or name

English

0 references

publication date

9 November 2011

1 reference

European Journal of Cancer Care

3 September 2017

published in

1 reference

3 September 2017

volume

21

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

242-250

1 reference

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Clinical application of the 70-gene profile: the MINDACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Public experiences, knowledge and expectations about medical genetics and the use of genetic information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Assessing patient readiness for the clinical adoption of personalized medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Genomic grade index is associated with response to chemotherapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Pharmacogenetics--legal, ethical and regulatory considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Ethical, Social and Legal Implications of Pharmacogenomics: A Critical Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Women's interest in gene expression analysis for breast cancer recurrence risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Reaching the parts other methods cannot reach: an introduction to qualitative methods in health and health services research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Development of the 21-gene assay and its application in clinical practice and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Genomic index of sensitivity to endocrine therapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Helpful communications during the diagnostic period: an interpretive description of patient preferences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Attributions and adjustment to life-threatening illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Women's experiences with genomic testing for breast cancer recurrence risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2354.2011.01300.X

10.1111/J.1365-2354.2011.01300.X

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference